ANALGESIC AND MUSCLE RELAXANT CAPLETS TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

IBUPROFEN; METHOCARBAMOL

可用日期:

TEVA CANADA LIMITED

ATC代码:

M03BA53

INN（国际名称）:

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

剂量:

200MG; 500MG

药物剂型:

TABLET

组成:

IBUPROFEN 200MG; METHOCARBAMOL 500MG

给药途径:

ORAL

每包单位数:

18/40

处方类型:

OTC

治疗领域:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

產品總結:

Active ingredient group (AIG) number: 0248961001; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2021-08-12

产品特点

1 | P a g e
PRODUCT MONOGRAPH
ANALGESIC & MUSCLE RELAXANT CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED
Date of Preparation:
30 Novopharm Court
January 8, 2013
Toronto, Canada
M1B 2K9
Control# 161025
2 | P a g e
TABLE OF CONTENTS
Clinical Pharmacology
..............................................................................................................................
3
Indications:
................................................................................................................................................
7
Contraindications
......................................................................................................................................
8
Warnings:
..................................................................................................................................................
8
Precautions
..............................................................................................................................................
12
Drug Interactions
....................................................................................................................................
13
Adverse Reactions
..................................................................................................................................
15
Symptoms and Treatment of Overdose
...................................................................................................
17
Dosage and
Administration.....................................................................................................................
18
Pharmaceutical Information
....................................................................................................................
19
Composition:
...........................................................................................................................................
21
Availability of Dosage Forms
..........................